Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $624.97 million. The enterprise value is $19.03 million.
| Market Cap | 624.97M |
| Enterprise Value | 19.03M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 2.23 billion shares outstanding. The number of shares has increased by 4.63% in one year.
| Shares Outstanding | 2.23B |
| Shares Change (YoY) | +4.63% |
| Shares Change (QoQ) | +1.38% |
| Owned by Insiders (%) | 6.42% |
| Owned by Institutions (%) | 75.79% |
| Float | 1.34B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.99 |
| Forward PS | 3.23 |
| PB Ratio | 0.63 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.34 |
| Quick Ratio | 5.12 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9,181.08 |
Financial Efficiency
Return on equity (ROE) is -70.60% and return on invested capital (ROIC) is -67.66%.
| Return on Equity (ROE) | -70.60% |
| Return on Assets (ROA) | -45.10% |
| Return on Capital (ROIC) | -67.66% |
| Revenue Per Employee | $171,344 |
| Profits Per Employee | -$700,994 |
| Employee Count | 1,218 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -122,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.98% in the last 52 weeks. The beta is 1.14, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -88.98% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 34.71 |
| Average Volume (20 Days) | 82,797,131 |
Short Selling Information
The latest short interest is 121.10 million, so 5.43% of the outstanding shares have been sold short.
| Short Interest | 121.10M |
| Short Previous Month | 245.41M |
| Short % of Shares Out | 5.43% |
| Short % of Float | 9.06% |
| Short Ratio (days to cover) | 1.78 |
Income Statement
In the last 12 months, DNA had revenue of $208.70 million and -$853.81 million in losses. Loss per share was -$0.44.
| Revenue | 208.70M |
| Gross Profit | 167.87M |
| Operating Income | -826.66M |
| Pretax Income | -853.93M |
| Net Income | -853.81M |
| EBITDA | -762.46M |
| EBIT | -853.84M |
| Loss Per Share | -$0.44 |
Balance Sheet
The company has $840.44 million in cash and $234.50 million in debt, giving a net cash position of $605.94 million or $0.27 per share.
| Cash & Cash Equivalents | 840.44M |
| Total Debt | 234.50M |
| Net Cash | 605.94M |
| Net Cash Per Share | $0.27 |
| Equity (Book Value) | 987.27M |
| Book Value Per Share | 0.44 |
| Working Capital | 733.98M |
Cash Flow
In the last 12 months, operating cash flow was -$294.17 million and capital expenditures -$24.26 million, giving a free cash flow of -$318.43 million.
| Operating Cash Flow | -294.17M |
| Capital Expenditures | -24.26M |
| Free Cash Flow | -318.43M |
| FCF Per Share | -$0.16 |
Margins
Gross margin is 80.43%, with operating and profit margins of -396.11% and -409.12%.
| Gross Margin | 80.43% |
| Operating Margin | -396.11% |
| Pretax Margin | -409.17% |
| Profit Margin | -409.12% |
| EBITDA Margin | -365.34% |
| EBIT Margin | -409.13% |
| FCF Margin | -152.58% |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.63% |
| Shareholder Yield | -4.63% |
| Earnings Yield | -136.62% |
| FCF Yield | -50.95% |
Analyst Forecast
The average price target for DNA is $1.40, which is 400.00% higher than the current price. The consensus rating is "Sell".
| Price Target | $1.40 |
| Price Target Difference | 400.00% |
| Analyst Consensus | Sell |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 24.90% |
| EPS Growth Forecast (5Y) | -15.70% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNA has an Altman Z-Score of -5.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.29 |
| Piotroski F-Score | 3 |